US WorldMeds is a specialty pharmaceutical company located in Louisville, Kentucky. Our mission is to develop, license and commercialize
unique and significant pharmaceuticals that address unmet medical needs or overcome the limitations of existing products.
- APOKYN is indicated for the acute, intermittent treatment of hypomobility, "off" episodes ("end-of-dose wearing off" and unpredictable "on/off" episodes) associated with advanced Parkinson's disease (PD). When injected during an off episode, APOKYN may enable people with PD to walk, talk, and move around more easily. APOKYN works quickly-within 20 minutes. APOKYN is used to reverse off-episode motor symptoms when they occur. APOKYN should be used in addition to oral PD medicines and does not replace them.
- MYOBLOC is indicated for the treatment of adults with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia. In numerous published studies, treatment with MYOBLOC resulted in a clinically and statistically significant improvement in head position and neck pain for patients with cervical dystonia.1-4 This was demonstrated in botulinum toxin naïve patients as well as patients previously treated with a botulinumtoxin.1-4 MYOBLOC was the first FDA-approved treatment for cervical dystonia, and remains the only type B botulinum toxin approved for use in the US.5,6
- Revonto (dantrolene sodium for injection) is indicated, along with appropriate supportive measures, for the management of fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. Revonto dramatically reduces reconstitution time of dantrolene sodium for injection to 20 seconds or until the solution is clear.
- XADAGO (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD)
experiencing “off” episodes. Limitations of Use: XADAGO has not been shown to be effective monotherapy for the treatment of PD.
1. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53(7):1439-1446. 2. Brin MF, Lew MF, Adler CH, et al. Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53(7):1431-1438.
3. Pappert EJ, Germanson T; Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord. 2008;23(4):510-517.
4. Data on file (MYO-026-1207). Malvern, PA: Solstice Neurosciences, Inc; 2007.
5. FDA approval letter. Myobloc for cervical dystonia. December 8, 2000.
6. FDA approval letter. Botox for cervical dystonia. December 21, 2000.